What Is a TGCT Tumor? Types, Recurrence, and Treatment

Tenosynovial giant cell tumor, or TGCT, is a rare neoplasm that grows in the tissue lining joints, tendon sheaths, and bursae. It is not a cancer in the traditional sense for most patients: the vast majority of TGCTs are benign, slow-growing masses that never spread to distant organs. But “benign” undersells the damage they can do. These tumors erode cartilage, destroy bone, cause chronic pain, and can leave a young adult facing joint replacement surgery decades earlier than anyone should. The biology behind TGCT is genuinely unusual, and recent drug approvals have changed the treatment landscape for patients whose tumors keep coming back after surgery.

What TGCT Actually Is

TGCT arises from the synovium, the thin membrane that lines the inside of joints and surrounds tendons. It was historically known by different names depending on where it showed up and how it grew, most commonly “giant cell tumor of the tendon sheath” for the small nodular form and “pigmented villonodular synovitis” (PVNS) for the larger, more aggressive form that fills an entire joint. These are now understood as the same disease with two patterns of growth, and the umbrella term TGCT covers both.

The localized type tends to appear as a firm, painless lump near a finger or toe tendon. The diffuse type infiltrates an entire joint lining, most often the knee, and causes swelling, stiffness, and progressive joint damage. Localized TGCT is the more common of the two and is generally easier to treat. Diffuse TGCT is less common but far more problematic, with higher recurrence rates and greater impact on daily life.

Two Forms, Two Very Different Experiences

Localized TGCT typically shows up in the hand. It presents as a slowly growing, painless nodule near a tendon, and patients often notice it simply because they can feel or see a bump. The diffuse form, by contrast, overwhelmingly favors the knee, though it can also affect the hip, ankle, and other large joints.¹ A study of foot and ankle TGCTs found that localized disease had a significantly shorter symptom duration before diagnosis (about six months on average) compared with diffuse disease, where symptoms often dragged on for roughly three years before someone figured out what was going on.²

The symptom profile for diffuse TGCT is striking in how much it disrupts function. In a study of patients with primarily diffuse disease, swelling was reported by about 86%, pain by 82%, stiffness by 73%, and reduced range of motion and joint instability each by about 64%.³ These are not vague complaints. Patients describe locking knees, inability to climb stairs, and giving up activities they used to enjoy. The tumor itself produces a brownish, blood-stained joint fluid because the tissue is loaded with hemosiderin, a pigment left behind when iron from old blood accumulates in the synovium.⁴

The CSF1 Mechanism Behind Tumor Growth

TGCT’s biology is unusual. Only a small fraction of the cells in a TGCT mass are actually neoplastic. The rest are recruited bystanders: macrophages, giant cells, and other immune cells drawn into the tumor by a powerful chemical signal. That signal is a protein called CSF1 (colony-stimulating factor 1), and its overproduction is the defining feature of TGCT.

The root cause in many cases is a chromosomal rearrangement. A translocation swaps pieces of chromosomes 1 and 2, fusing the CSF1 gene to a partner gene called COL6A3. Because COL6A3 has a very active promoter, the fused gene churns out far more CSF1 than the cell would normally produce.⁵ Other translocation partners can also drive CSF1 overexpression, and in some cases the regulatory elements of CSF1 are disrupted rather than fused to a specific partner, but the downstream result is the same: a flood of CSF1 pouring into the joint environment.⁶

What makes this especially interesting is the “landscape effect.” CSF1 is produced by neoplastic cells, but those neoplastic cells themselves do not respond to it. They lack the receptor (CSF1R) that reads the signal. Instead, CSF1 acts as a beacon that pulls in macrophages and other immune cells from the surrounding tissue. These recruited macrophages do express CSF1R and pile into the joint in enormous numbers, eventually forming the bulk of the tumor mass.⁷ The macrophages also polarize toward a tissue-remodeling state that contributes to cartilage erosion and joint destruction.⁸ So the tumor is, in essence, a small cluster of misbehaving cells that trick the immune system into building a destructive mass around them.

How TGCT Is Diagnosed

TGCT is often suspected when a patient presents with unexplained joint swelling, recurrent bloody joint effusions, or a palpable soft-tissue mass near a tendon. MRI is the imaging tool of choice and can be highly suggestive of the diagnosis. The hemosiderin deposits within the tumor produce a characteristic dark signal on certain MRI sequences, sometimes described as a “blooming artifact.” However, this finding is more reliable in diffuse disease (present in about 86% of cases) than in the localized nodular form (only about 27%), and there can be substantial disagreement between radiologists reading the same images.⁹ Because imaging alone is not always definitive, biopsy remains important for confirmation.

Under the microscope, TGCT has a recognizable appearance: sheets of bland, rounded cells with pink cytoplasm, scattered multinucleated giant cells (which give the tumor its name), clusters of foamy macrophages, and macrophages loaded with hemosiderin pigment.¹⁰ The mix of cell types reflects the tumor’s biology, in which a small neoplastic population is vastly outnumbered by recruited immune cells.

Surgery and the Recurrence Problem

For localized TGCT, surgery is usually straightforward and curative. A single excision removes the nodule, and recurrence rates are low. A study of 50 hand cases found a recurrence rate of just 6% over an average follow-up of seven years, with the main risk factor being tumor location near certain finger joints.¹¹ A broader meta-analysis of foot and ankle TGCT put the localized recurrence rate at about 7%.¹²

Diffuse TGCT is a different story. Because the tumor infiltrates the entire joint lining, completely removing every bit of diseased tissue is technically difficult. Recurrence rates for diffuse disease can reach as high as roughly 50%.¹³ The same foot and ankle meta-analysis found a 21% recurrence rate for diffuse disease, with the vast majority of recurrences (86%) appearing within the first five years.¹⁴

For diffuse TGCT of the knee, surgeons face a choice between open surgery and arthroscopic approaches. A systematic review found that open synovectomy had lower recurrence rates, likely because the surgeon can see and reach more tissue. Arthroscopic surgery, on the other hand, produced fewer complications and less post-operative stiffness. The review’s conclusion favored open surgery when the primary goal is preventing the tumor from coming back.¹⁵ Some centers combine arthroscopic surgery with adjuvant low-dose radiation. In one series of 18 patients treated this way, functional scores improved dramatically over a follow-up averaging nearly six years, moving from “poor” to “good” on standardized knee assessments.¹⁶

Targeted Drugs That Block CSF1R

Because TGCT’s growth depends so heavily on the CSF1/CSF1R signaling axis, blocking that pathway has been a logical drug target. Two CSF1R inhibitors have now been tested in large, randomized trials.

Pexidartinib (brand name Turalio) was the first to gain approval. In the phase 3 ENLIVEN trial, about 39% of patients with advanced TGCT had a measurable tumor response at 25 weeks, compared with 0% on placebo. With longer treatment, the best overall response rate climbed to about 53%. Patients also gained range of motion and reported better physical function and less stiffness.¹⁷ However, pexidartinib carries a serious liver toxicity risk, which led to its approval coming with a mandatory risk management program in the United States. Prescribers must enroll patients in a registry, check liver enzymes at baseline and regularly during treatment, and watch for signs of a rare but dangerous condition called vanishing bile duct syndrome.¹⁸

Five-year data from that safety program showed that roughly 6% of patients treated with pexidartinib experienced liver-related adverse events suggestive of serious injury. One confirmed case of vanishing bile duct syndrome occurred during the most recent two-year reporting window, and the patient was recovering at last follow-up.¹⁹ Earlier three-year data found that all hepatic events appeared within the first two months of therapy, reinforcing the value of close monitoring during that window.²⁰

Vimseltinib is the newer entrant. In the phase 3 MOTION trial, it achieved a 40% response rate at 25 weeks versus 0% for placebo, with nearly all treated patients experiencing some degree of tumor shrinkage. Patients also gained significant range of motion in their affected joints. The side-effect profile differed from pexidartinib’s: the most common issues were swelling around the eyes and face, fatigue, itching, and headache. Elevated creatine phosphokinase was the only grade 3 or 4 lab abnormality seen in more than 5% of patients, and it was not associated with muscle damage. Crucially, vimseltinib showed no evidence of the cholestatic liver toxicity that has been pexidartinib’s main liability.²¹ If that liver safety advantage holds up with longer follow-up, vimseltinib could become a preferred systemic option for patients who need medical therapy.

Who Gets TGCT and When It Gets Missed

TGCT affects young adults, with peak onset in the 20s through 40s. It occurs across all demographics, though some series report a slight female predominance in localized disease.²² The fact that it hits people in their most active years is part of what makes it so disruptive. A 30-year-old with chronic knee swelling and pain is often told they have a meniscus tear, arthritis, or something more common, and the rarity of TGCT means many clinicians have never seen a case.

Delayed diagnosis is a well-documented problem. Over half of patients wait a year or more from symptom onset to getting the correct diagnosis.²³ During that time, joint damage can accumulate. The disease leads to progressive cartilage loss and secondary osteoarthritis, and by the time some patients are diagnosed, enough destruction has occurred that joint replacement becomes necessary.²⁴

Impact on Daily Life and Economic Costs

Patients with TGCT report significantly lower quality of life than the general population, with the greatest problems in pain, mobility, and the ability to perform everyday activities.²⁵ People with diffuse disease fare measurably worse than those with localized tumors on standardized physical function scores.²⁶ An expert consensus panel has emphasized that although TGCT is usually not life-threatening, its chronic pain and functional limitations create a real disease burden that can rival more familiar conditions.²⁷

The financial impact is substantial, too. In the U.S. workforce, patients with TGCT had hospital admission rates nearly three times higher than matched controls, more than double the outpatient visits, and roughly 2.6 times as many work-loss days. Annual healthcare costs were about $9,400 higher, and lost productivity added another $2,700 or so on top of that.²⁸ For a “benign” condition, those numbers are sobering.

TGCT in Children and Adolescents

Although TGCT is predominantly a disease of adults, it does occur in children. The knee is the most common site in pediatric cases, and localized nodular disease accounts for the majority.²⁹ Reassuringly, studies that have compared pediatric and adult TGCT directly have found no significant differences in symptoms, treatment approach, or recurrence-free survival.³⁰

Where children do differ is in the diagnostic journey. Registry data show that over 60% of pediatric patients were initially misdiagnosed, a significantly higher rate than in adults. Children with TGCT were also more likely to undergo joint aspirations before anyone suspected the true diagnosis. Pediatric patients with diffuse disease averaged over three surgeries, compared with fewer than two for those with localized tumors.³¹ The takeaway for families is that persistent, unexplained joint swelling in a child warrants imaging and referral rather than repeated aspiration and watchful waiting.

When TGCT Turns Malignant

Malignant TGCT exists, but it is exceedingly rare. It can arise within or alongside a pre-existing benign TGCT, or it can appear without an obvious benign precursor. In one case series of ten patients, the tumor presented in a variety of joints, and under the microscope the malignant areas sat right next to recognizable benign TGCT tissue. Follow-up showed local recurrences in three patients and lung metastases in three others, with three patients ultimately dying of their disease.³²

Malignant TGCT favors the lower extremities. In a separate series of six patients, all tumors arose in the legs, and all six developed lung metastases. Four of the five patients with evaluable imaging also had lymph node spread.³³ This is starkly different from ordinary TGCT, which essentially never metastasizes. The clinical behavior of malignant TGCT is aggressive enough that it has prompted some pathologists to wonder whether it deserves recognition as the “true” synovial sarcoma, a provocative framing given that the tumor currently called synovial sarcoma has no clear connection to the synovium.³⁴ That debate remains unresolved, but for patients the practical message is straightforward: any TGCT that grows rapidly, develops new areas of necrosis, or behaves differently than expected on imaging should be re-biopsied to rule out malignant transformation.³⁵